Nat Commun: p32 CAR-T cells: a potential treatment option for glioblastoma

Malignant glioma is the most common type of primary brain tumor in the central nervous system.
It has a high degree of invasiveness and a frustrating prognosis
.

Glioblastoma (GBM) is the most aggressive and lethal form of malignant glioma, with an average survival time of only 12-18 months

Malignant glioma is the most common type of primary brain tumor in the central nervous system.

The current standard of care for newly diagnosed GBM patients includes maximum surgical resection, radiotherapy and adjuvant chemotherapy (temozolomide)
.

However, the efficacy of this treatment strategy is limited, and patients will experience disease progression or recurrence

The current standard of care for newly diagnosed GBM patients includes maximum surgical resection, radiotherapy and adjuvant chemotherapy (temozolomide)

Although recent preclinical and clinical studies have confirmed the feasibility of CAR (chimeric antigen receptor)-T cell immunotherapy in glioblastoma, tumor heterogeneity and antigen loss are still the most important issues that need to be addressed.
One of the challenges
.

immunity

Analysis of the expression level of p32 in the sample

Analysis of the expression level of p32 in the sample

In this study, the researchers found that p32/gC1qR/HABP/C1qBP is specifically expressed on the surface of glioma cells, which has also become a suitable tumor-associated antigen for redirecting CAR-T cell therapy
.

p32/gC1qR/HABP/C1qBP is specifically expressed on the surface of glioma cells, which has also become a suitable tumor-associated antigen for redirecting CAR-T cell therapy
.

p32/gC1qR/HABP/C1qBP is specifically expressed on the surface of glioma cells, which has also become a suitable tumor-associated antigen for redirecting CAR-T cell therapy

Anti-tumor response of p32 CAR-T cells to glioma

Anti-tumor response of p32 CAR-T cells to glioma

Researchers constructed p32 CAR-T cells and found that they can recognize and specifically eliminate p32-expressing glioma cells and tumor-derived endothelial cells in vitro, and in orthotopic syngeneic and xenograft mouse models, they Can control tumor growth
.

In summary, the results of the study reveal that p32 CAR-T cells can be used as a treatment option for patients with glioblastoma
.

The results of the study revealed that p32 CAR-T cells can be used as a treatment option for patients with glioblastoma
.

The results of the study revealed that p32 CAR-T cells can be used as a treatment option for patients with glioblastoma

P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas.

Leave a message here